Pharmacological treatments remain an area of debate, with cholinesterase inhibitors and memantine showing potential benefits in lvPPA, which shares an Alzheimer’s disease-related pathology, while frontotemporal forms of PPA lack effective pharmacological options [103]. This evidence concerns the gene BCHE and primary progressive aphasia.